10x Genomics, Inc.
- Jurisdiction
United States - LEI
5493003Z6741WNLG7H43 - ISIN
US88025U1097 (TXG )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Read full profile
Fundamentals
- Net revenue
€549.70M - Gross margin
69.5% - EBIT
-€85.74M - EBIT margin
-15.6% - Net income
-€72.16M - Net margin
-13.1%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
|
|
|
|
| Saxonov Serge | Chief Executive Officer |
|
|
|
|
| Taich Adam | Chief Financial Officer |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Cathie Wood |
|
|
|
Buy |
| Peter Brown |
|
|
|
Buy |